Clinical and Cost-Effectiveness of Omalizumab in Concomitant Asthma and Chronic Rhinosinusitis with Nasal Polyps: A Real-World Exploratory Study

Purpose

Severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) frequently coexist, representing the severe "United Airway Disease" (UAD) phenotype. Although omalizumab is approved for both conditions individually, real-world evaluations of its clinical and economic viability for this concomitant phenotype remain limited. We evaluated the cost-effectiveness of omalizumab add-on therapy in Chinese adults with UAD.